Higher Risk of Hypoglycemia with Glimepiride Versus Vildagliptin in Patients with Type 2 Diabetes is not Driven by High Doses of Glimepiride: Divergent Patient Susceptibilities?

INTRODUCTION: In a previously published study, vildagliptin showed a reduced risk of hypoglycemia versus glimepiride as add-on therapy to metformin at similar efficacy. Glimepiride was titrated from a starting dose of 2 mg/day to a maximum dose of 6 mg/day. It is usually assumed that the increased h...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahrén, Bo, Foley, James Edward, Dejager, Sylvie, Akacha, Mouna, Shao, Qing, Heimann, Guenter, Dworak, Markus, Schweizer, Anja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4269641/
https://www.ncbi.nlm.nih.gov/pubmed/25230877
http://dx.doi.org/10.1007/s13300-014-0082-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4269641/
https://www.ncbi.nlm.nih.gov/pubmed/25230877
http://dx.doi.org/10.1007/s13300-014-0082-y

Ejemplares similares